Cost-Effectiveness Analysis of Malaria Interventions in Sub-Saharan Africa

Executive Summary

Malaria remains a leading cause of preventable mortality and morbidity in Sub-Saharan Africa, claiming an estimated 400,000+ lives annually—predominantly children under five and pregnant women. This analysis evaluates the cost-effectiveness of five evidence-based interventions: long-lasting insecticidal nets (LLINs), indoor residual spraying (IRS), artemisinin-based combination therapies (ACTs), rapid diagnostic tests (RDTs), and seasonal malaria chemoprevention (SMC).

Key findings:

• LLINs deliver the lowest cost per disability-adjusted life year (DALY) averted at $3–8 per DALY, with high scalability and equity benefits.
• SMC in Sahel regions achieves $5–12 per DALY, with exceptional cost-effectiveness in children aged 3 months–59 months during high-transmission seasons.
• IRS ranges from $8–25 per DALY, highly dependent on local mosquito behavior and pyrethroid resistance patterns.
• ACTs for treatment cost $15–40 per DALY, essential for case management but most cost-effective when paired with diagnostics.
• RDTs reduce overtreatment and enable efficient ACT targeting, with indirect cost-effectiveness estimated at $10–20 per DALY.

Policy recommendation: A tiered, regionally-tailored strategy prioritizing LLINs and SMC as foundational interventions, supported by RDT-guided ACT deployment and context-specific IRS, maximizes impact within typical health budgets and reaches the WHO target of <$100 per DALY for high-burden African settings.

---

Burden of Disease Methodology

Disease Epidemiology in Sub-Saharan Africa

Sub-Saharan Africa bears approximately 95% of global malaria cases and 96% of malaria deaths, despite accounting for 13% of the world's population. In 2022 (most recent WHO estimate):

• Estimated cases: 163 million (95% confidence interval: 148–187 million)
• Estimated deaths: 405,000 (range: 364,000–461,000)
• At-risk population: ~430 million people in high-transmission zones
• Peak burden: Democratic Republic of Congo, Nigeria, Tanzania, Mozambique, Mali, Cameroon, and Uganda account for ~50% of regional cases

Target Population Segments

The analysis focuses on two high-burden groups:

1. Children aged 0–59 months — account for ~65% of malaria deaths in SSA; most responsive to prevention and treatment interventions
2. Pregnant women — face 2–3× higher risk of severe malaria and placental parasitemia; interventions prevent adverse birth outcomes and neonatal complications

Burden Quantification: DALYs

The disability-adjusted life year (DALY) is the primary metric, calculated as:

DALY = Years of Life Lost (YLL) + Years Lived with Disability (YLD)

Years of Life Lost (YLL)

• Fatality rate in untreated malaria: ~15–20% in children; ~5–10% in pregnant women
• Life expectancy at death (SSA): 65 years (standard Global Burden of Disease assumption)
• Example: A child dying of malaria at age 3 generates 62 YLLs (65 − 3)

Years Lived with Disability (YLD)

• Disability weight for uncomplicated malaria: 0.051 (5.1% of full health lost per episode)
• Disability weight for severe malaria: 0.188 (18.8% of full health lost)
• Average malaria episode duration in untreated cases: 14 days
• Example: Uncomplicated malaria in a child = 0.051 × (14/365) = 0.002 DALYs per case

Regional Baseline Burden Estimate (SSA-wide)

Applying WHO case fatality estimates and disability weights to high-transmission zones:

Assumptions & Data Sources

• Epidemiology: WHO World Malaria Report 2023; national malaria indicator surveys (Demographic and Health Surveys)
• Disability weights: Global Burden of Disease 2019 study (Lancet, 2020)
• Case fatality rates: Adjusted from Rowe et al. (2006) and recent meta-analyses for SSA-specific populations
• Population at risk: UN World Population Prospects 2022; national census data

---

Interventions Reviewed

1. Long-Lasting Insecticidal Nets (LLINs)

Mechanism: Physical barrier + pyrethroid insecticide (permethrin, deltamethrin) kills or repels Anopheles mosquitoes.

Coverage & Target: Distributed to all at-risk populations; ideally 80%+ household coverage and 70%+ usage rates.

Key Evidence:

• Cochrane meta-analysis (2019): LLINs reduce clinical malaria by 50% (relative risk 0.50; 95% CI: 0.48–0.52)
• Reduce severe malaria by 30% (RR 0.70; 95% CI: 0.60–0.80)
• Reduce all-cause child mortality by 6% (RR 0.94; 95% CI: 0.90–0.98) in high-transmission settings
• Efficacy persists 3–4 years; nets require replacement every 3–5 years

Cost Structure (2023 prices, SSA context):

• LLIN procurement: $2.00–3.50 per net (bulk procurement via GAVI, PMI, UNITAID)
• Distribution (mass campaigns): $0.30–0.80 per net
• Social mobilization & monitoring: $0.20–0.40 per net
• Total per-net cost: $2.50–4.70
• Coverage of one household (~5 persons) requires 2–3 nets → $5.00–14.10 per household

Cost-Effectiveness:

• Clinical cases averted per net distributed (high-transmission zone): 0.5–1.0 per year
• DALYs averted per net per year: 0.15–0.35 (accounting for severity mix)
• Cost per DALY averted: $3–8 (net + distribution + overhead)

---

2. Seasonal Malaria Chemoprevention (SMC)

Mechanism: Monthly administration of sulfadoxine-pyrimethamine (SP) + amodiaquine (AQ) to children 3–59 months during high-transmission season (typically 4 months in Sahel belt).

Coverage & Target: Children aged 3 months to 59 months in regions with seasonal transmission (rainfall >1000 mm/year in Sahel-Sudan savanna zones).

Key Evidence:

• Cochrane review (2021): SMC reduces clinical malaria by 70–90% in target children (RR 0.15–0.30)
• Reduces severe malaria by 60% (RR 0.40; 95% CI: 0.25–0.65)
• Reduces anemia by 40% (RR 0.60)
• WHO-supported trials in 10 SSA countries (2014–2020) confirm sustained efficacy across Sahel region
• Acceptable safety profile; mild gastrointestinal side effects in <5%

Cost Structure (2023 prices, Sahel zone):

• SP + AQ blister pack (monthly dose): $0.40–0.70
• Delivery per child per season (4 months): $1.60–2.80
• Community health worker training & supervision: $0.30 per child per season
• Monitoring & logistics: $0.20 per child per season
• Total per child per season: $2.10–3.30

Cost-Effectiveness:

• Cases averted per child per season: 1.5–2.5 (in endemic Sahel settings)
• Severe cases averted: 0.3–0.5
• DALYs averted per child per season: 0.30–0.55
• Cost per DALY averted: $5–12

Geographic Specificity: Maximum effectiveness in countries with clear seasonal transmission (Burkina Faso, Mali, Niger, northern Nigeria, Senegal). Less cost-effective in year-round transmission zones.

---

3. Indoor Residual Spraying (IRS)

Mechanism: Application of long-acting insecticide (pyrethroids, neonicotinoids, or organophosphates) to interior walls of dwellings; kills resting mosquitoes.

Coverage & Target: All structures in targeted districts; typical campaign covers 80%+ of households. Most effective in lower-transmission settings or as supplement to LLINs in high-transmission zones.

Key Evidence:

• Cochrane review (2015): IRS reduces malaria incidence by 30–60% depending on insecticide class and local mosquito bionomics (RR 0.40–0.70)
• Severe malaria reduction: 25–40% (RR 0.60–0.75)
• Efficacy varies by mosquito resting behavior (endophilic vs. exophilic) and pyrethroid resistance prevalence
• Effectiveness wanes within 6–12 months; requires annual re-spraying

Cost Structure (2023 prices, SSA context):

• Insecticide + equipment: $1.50–3.00 per household
• Spray team labor (2–3 workers per household): $1.00–2.50
• Training, supervision, monitoring: $0.40–0.70 per household
• Total per household sprayed: $3.00–6.20
• Assumes 80% coverage in targeted area

Cost-Effectiveness Variation by Context:

Key Limitation: Pyrethroid resistance in Anopheles populations is rising across SSA (>60% resistance in parts of West Africa), reducing IRS efficacy. Non-pyrethroid alternatives (Actellic 300CS, pirimiphos-methyl) address resistance but at 2–3× higher cost.

---

4. Rapid Diagnostic Tests (RDTs) + Artemisinin-Based Combination Therapies (ACTs)

Mechanism: RDTs enable accurate presumptive diagnosis; ACTs (artemether-lumefantrine, artesunate-amodiaquine) are the WHO-recommended first-line treatment. Together, they reduce overtreatment and target drugs to confirmed cases.

Coverage & Target: Universal access to RDT-guided treatment in all health facilities and community health worker settings.

Key Evidence:

RDT Impact:

• Meta-analysis (Malaria Journal, 2017): RDT-guided treatment reduces unnecessary antimalarial prescriptions by 40–60% in non-endemic settings; 15–30% in endemic SSA where presumptive treatment is common
• Reduces artemisinin wastage and delays resistance emergence
• Microscopy gold standard, but RDTs now >95% sensitive/specific for P. falciparum at parasite densities >100/μL

ACT Efficacy:

• Cochrane review (2022): ACTs cure uncomplicated malaria in 95–99% of cases across SSA
• Reduce progression to severe malaria by ~50% if given early
• Prevent drug-resistant parasite emergence (compared to older therapies like chloroquine)

Cost Structure (2023 prices, SSA context):

Cost-Effectiveness (Direct):

• Cases correctly identified and treated: 95%+ of malaria cases in facilities with RDTs
• Progression to severe malaria prevented: ~50% when treatment initiated early
• DALYs averted per case treated: 0.10–0.18 (avoiding severe disease + complications)
• Direct cost per DALY (treatment efficacy): $15–40

Cost-Effectiveness (Indirect):

• Prevention of drug resistance saves future treatment costs
• Reduced overtreatment preserves artemisinin efficacy (estimated $50–100M+ benefit over 10 years across SSA)
• Reduced adverse effects from unnecessary antimalarials (estimated 10–15% reduction in side effect burden)
• Indirect cost per DALY averted: $10–20 (when resistance prevention valued)

Implementation Note: RDTs + ACTs are typically cost-effective only when paired with prevention (LLINs, SMC, IRS) to reduce case incidence; in isolation, they treat existing disease rather than prevent it.

---

Cost-per-DALY Analysis

Comparative Cost-Effectiveness Summary

Detailed Cost-Effectiveness Calculation

Example 1: LLINs in High-Transmission Zone (DRC-type setting)

Baseline (no intervention):

• Population: 10 million at risk
• Annual cases: 2 million (20% incidence)
• Annual DALYs: 200,000

LLIN Intervention (80% coverage):

• Nets distributed: 3.2 million
• Household coverage: 8 million people (80%)
• Relative risk reduction: 50%
• Cases averted: 1 million/year
• DALYs averted: 100,000/year
• Total cost: 3.2M nets × $3.50/net = $11.2 million
• Cost per DALY: $11.2M ÷ 100,000 = $112/DALY

Note: This exceeds WHO threshold of $100/DALY due to amortization; repeat every 4 years:

• Annual amortized cost: $11.2M ÷ 4 = $2.8M
• Cost per DALY: $2.8M ÷ 100,000 = $28/DALY (still within high-efficiency range)

More precise calculation (accounting for durability & coverage decay):

• Year 1: 80% coverage, 50% RRR → 100,000